2004 Surveillance Slides
This is an archived document. The links
and content are no longer being updated.
Return to 2004 Surveillance Slides
Main Menu
Primary Anti-TB Drug Resistance
United States, 1993–2004
|
Slide 19. Primary Anti-TB Drug Resistance, United
States, 1993–2004. Primary drug resistance is shown
for the previous 12 years. The graph starts in 1993, the year in
which the individual TB case reports submitted to the national surveillance
system began collecting information on initial susceptibility test
results for patients with culture-positive TB. Data were available
for more than 85% of culture-positive cases for each year. Primary
resistance was calculated by using data from persons with no reported
prior TB episode. Resistance to at least isoniazid remained between
7.0% and 8.4%. However, resistance to at least isoniazid and rifampin,
known as multidrug-resistant TB (MDR TB), decreased from 2.5% in
1993 to approximately 1.0% each year during 1997-2004. |
Back to 2004 Surveillance Slides Main
Page |
Last Reviewed: 05/18/2008 Content Source: Division of Tuberculosis Elimination
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Back to Top of Page
You will need Adobe Acrobat Reader
v5.0 or higher to read pages that are in PDF format. Download the Adobe Acrobat Reader.
If you have difficulty accessing any
material on the DTBE Web site because of a disability, please contact
us in writing or via telephone and we will work with you to make the information
available.
Division of Tuberculosis Elimination
Attn: Content Manager, DTBE Web site
Centers for Disease Control and Prevention
1600 Clifton Rd., NE Mailstop E-10
Atlanta, GA 30333
CDC-INFO at (1-800) 232-4636
TTY: 1 (888) 232-6348
E-mail: tbinfo@cdc.gov
|
Home |
Site Map
| Contact Us
Accessibility
| Privacy Policy Notice |
FOIA
| USA.gov
CDC Home |
Search |
Health Topics A-Z
Centers for Disease Control & Prevention
National Center for HIV/AIDS,
Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination Please send comments/suggestions/requests to:
CDCINFO@cdc.gov
|